Use of long-acting contraceptives in therapy of mastopathy
https://doi.org/10.14341/probl12165
Abstract
Effects of long-acting contraceptives on mammary glands of patients with diffuse fibrocystic mastopathy were under study. A total of 206 women aged 17 to 38 were examined. In 50 of them fibrocystic mastopathy was detected by palpation, noncontrast mammography, and ultrasonic examination. On days 5-7 of the cycle the patients were injected 1 ml of depot prover or noristerate or subcutaneously implanted norplant. Injections of the two former agents were repeated in 3 months if necessary. Control examinations were carried out 3 months to 5 years after the contraceptives were started. The results indicate that long-acting contraceptives did not cause any negative changes in the course of mastopathy in 32 of 50 women. In 18 women the general status improved (pain and induration in the mammary glands disappeared), mammographic, thermographic, and ultrasonic data improved, this prompting us to continue our research.
About the Authors
A. G. KhomasuridzeGeorgia
R. A. Manusharova
Georgia
N. G. Marsaghishvili
Georgia
References
1. Горин Б. Я. Патогенетическое обоснование к изучению распространенности формирования групп риска в профилактике рака молочной железы: Автореф. дис. ... канд. мед. наук.— Алма-Ата, 1980.
2. Прилепская В.Н.// Вопр. охр. мат.—1980.—№ 3.— С. 58—62.
3. Серое В. Н., Прилепская В. Н.. Самойлова Т. К. //Акуш. и гин,—1986,—№ 11.—С. 11 — 15.
Review
For citations:
Khomasuridze A.G., Manusharova R.A., Marsaghishvili N.G. Use of long-acting contraceptives in therapy of mastopathy. Problems of Endocrinology. 1994;40(5):29-30. (In Russ.) https://doi.org/10.14341/probl12165

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).